galinpepimut-S Updated Oct 28
Watch for the topline Phase 3 REGAL overall survival readout, expected within the next two months (Q4 2026). A positive result showing statistically significant survival benefit could drive the stock toward analyst targets of $30-$35, while a miss or marginal result would likely devastate the stock given the company's pre-revenue status and dependence on this single asset. The ongoing securities investigation adds a secondary legal risk to monitor.
- The REGAL trial passed its pre-specified futility analysis in January 2025, suggesting the Data Monitoring Committee saw enough efficacy signal to continue (source: cancernetwork.com)
- The trial took longer than originally expected to reach 80 events, which could indicate patients on galinpepimut-S are living longer than the statistical assumptions predicted (source: intobiotech.com)
- Major institutional investors accumulated heavily in Q2 2026: BlackRock held $222M, State Street added 55% to reach $192M, and Vanguard added 48% to reach $121M
- STAT News biotech columnist Adam Feuerstein predicted the REGAL trial will fail, stating galinpepimut-S is not expected to show a survival benefit over standard of care (source: statnews.com)
- The trial was delayed by nearly a year to reach 80 events, raising significant doubts about the magnitude of any potential efficacy signal (source: statnews.com)
- Pomerantz LLP and other law firms have launched securities fraud investigations into whether SELLAS delayed disclosing that the 80th event had been reached, causing a 13% stock drop on August 28, 2026 (source: pomlaw.com)